Tigermed Insight

We believe knowledge needs to be shared for better research to address unmet patients needs.

Navigating Challenges and Best Practices for Regulatory and Clinical Success in Cell and Gene Therapies

Making Your Mark in the Competitive GLP-1 Market

Embracing Decentralized Tools for a More Cost-Effective Trial

Beyond Borders: Pioneering Global Clinical Trials for 20 Years and Counting

Annual Report on Clinical Trials for New Drug Registration in China (2022)

The 2021 Drug Review Annual Report

Clinical Trials Ultimately Aim to Improve Human Health

Clinical value is top priority in cancer drug trials, CDE says.

ICH Guidelines in China: Where are we now?

More Chinese biotech startups are testing their new drugs but slowly, CDE report reveals.

Risk-based Quality Management：A Transformative Approach for Clinical Trial Monitoring

The Breakthrough Therapy Designation in China: A Magnet for Foreign Companies

A Revolutionary Approach for Evolutionary Development – A Conversation with James Brook

Video: Including China into Your Global Drug Development Strategy

Increasing More Opportunities for Better Treatment – A conversation with Dr. Charles Schmidt

China Authority is Taking Initiatives to Enhance its Drug Administration Capabilities

What’s New for Getting Breakthrough Therapy Designation for Drugs in China？